Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease

Last updated:
2026-07-11
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIVIPANSEL (GMI 1070) IN THE TREATMENT OF VASO OCCLUSIVE CRISIS IN HOSPITALIZED SUBJECTS WITH SICKLE CELL DISEASE

Intervention/treatment:
RIVIPANSEL (GMI-1070)
Medical condition:
SICKLE CELL DISEASE
Protocol code:
B5201002
Control number:
177625
Status:
Closed
Approved:
September 25, 2014
Date Completed:
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT02187003
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
6 Years and older
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Head of Regulatory
Organization
Biossil Inc.
Phone:
978-245-7397
Sponsor
PFIZER CANADA INC

Locations

Alberta

Grey Nuns Community Hospital
Edmonton, Alberta, T6L 5X8
Kaye Edmonton Clinic 3 C
Edmonton, Alberta, T6G 1Z1
Miseracordia Community Hospital
Edmonton, Alberta, T5R 4H5
Research transition Facility
Edmonton, Alberta, T6G 2V2
Royal Alexandra Hospital
Edmonton, Alberta, T5H 3V9
Stollery Children's Hospital
Edmonton, Alberta, T6G 2B7
University of Alberta Hospital
Edmonton, Alberta, T6G 2B7
University of Alberta Hospital, Pharmacy Services
Edmonton, Alberta, T6G 1Z1

British Columbia

St. Paul's Hospital
Vancouver, British Columbia, V6E 1M7
St. Paul's Hospital
Vancouver, British Columbia, V6Z 1Y6

Ontario

Children's Hospital Of Eastern Ontario
Ottawa, Ontario, K1H 8L1
The Hospital for Sick Children
Toronto, Ontario, M5G1X8
University Health Network, Toronto General Hospital
Toronto, Ontario, M5G 2C4

Quebec

Centre Hospitalier Universitaire Sainte-Justine
Montreal, Quebec, H3T 1C5
McGill University Health Centre, Royal Victoria Hospital
Montreal, Quebec, H4A 3J1
The Montreal Children's Hospital/ McGill University Health Centre
Montreal, Quebec, H4A 3J1

Results

See the results from the trial NCT02187003. This is an external link. The information is not authorized by the Government of Canada.

Date posted:
Did you find what you were looking for?